A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled,
parallel groups study aimed to evaluate the safety, tolerability and the efficacy of
riociguat compared with placebo in patients with sickle cell disease (SCD).